Vinge has advised Samhällsbyggnadsbolaget i Norden AB (publ) (”SBB”) in connection with its newly established subsidiary SBB Residential Property AB entering into a capital raise agreement with an investment fund managed by Morgan Stanley Real Estate Investing (“MSREI”).

Pursuant to the agreement, SBB Residential Property AB will issue SEK 2.36 billion of preference shares to MSREI. The preference shares will be issued by an entity to be named SBB Residential Property AB forming a new group within SBB.

Following the transaction, MSREI will hold a minority stake in SBB Residential Property AB. The transaction is subject to customary closing conditions but not competition clearance. Closing will occur as soon as all closing conditions have been fulfilled, which is expected to occur around mid August 2023.

Vinge’s team consisted mainly of Mikael Ståhl, Jesper Schönbeck, Rikard Lindahl, Niclas Winnberg, Helena Göransson, Ulrich Ziche, Maria Dahlin Kolvik, Kristoffer Larsson, Frida Ställborn, Joel Magnusson, Kamyar Najmi, Nour Makie, Ida Redander and Filip Magnusson.


Vinge advises Spetses Investments and Bacara Holdings on the public offer for IRRAS

A bid consortium, acting through IR Holding Bidco Inc, has announced and completed a public offer to the shareholders of IRRAS AB (publ). The consortium included, among others, IRRAS’ two largest shareholders, Spetses Investments Ltd and Bacara Holdings Limited, both advised by Vinge.
October 03, 2023

Vinge advises SAGA Diagnostics AB on convertible note issue

SAGA Diagnostics AB, a cancer diagnostics and disease monitoring company, has carried out a convertible note issue of approximately SEK 144 million. Vinge advised SAGA Diagnostics in connection with the transaction.
September 28, 2023

Vinge advises Repligen Corporation in connection with the acquisition of Metenova

Vinge has advised Repligen Corporation and subsidiaries ("Repligen"), a multinational life sciences group that develops and commercializes highly innovative bioprocess technologies and systems that enable efficiency in the biopharmaceutical manufacturing process, in connection with its acquisition of Metenova Holding AB with subsidiaries (“Metenova”).
September 27, 2023